Subscribe to our RSS feed

The Latest Stories By Guest Authors

  • Sort it out (#141)
  • Stepping up the pace for trans people, gay men, and other MSM: a community perspective
  • Making sense of AIDS 2014
  • To test or not to test for HIV?  That is the question…
  • I'm an HIV Physician. And I'm starting PrEP

Guest Authors

Guest Authors
The Revolving Door is the place where we publish occasional articles by guest writers. If you would like to submit an article for publication, please contact editor Bob Leahy at This email address is being protected from spambots. You need JavaScript enabled to view it.
May21

New US guidelines recommend PrEP

Wednesday, 21 May 2014 Written by // Guest Authors - Revolving Door Categories // As Prevention , Gay Men, Health, Sexual Health, International , Treatment, Population Specific , Revolving Door, Guest Authors

From aidsmap, CDC recommends pre-exposure prophylaxis for any non-monogamous gay man who has had condomless sex in the last six months

New US guidelines recommend PrEP

This article by Gus Cairns first appeared on aidsmap here

The US Centers for Disease Control and Prevention (CDC) has released new guidelines recommending that pre-exposure prophylaxis (PrEP) should be considered for anyone HIV-negative who:

  • Is in an ongoing sexual relationship with a partner living with HIV.
  • Is a gay or bisexual man who has had sex without a condom or has been diagnosed with a sexually transmitted infection within the past six months, and is not in a mutually monogamous relationship with a partner who recently tested HIV negative.
  • Is a heterosexual man or woman who does not always use condoms when having sex with partners known to be at risk for HIV (for example, people who inject drugs or bisexual male partners of unknown HIV status), and is not in a mutually monogamous relationship with a partner who recently tested HIV negative.
  • Has, within the past six months, injected drugs and shared equipment or been in a treatment programme for injection drug use.

The US Food and Drug Administration (FDA) approved PrEP on 17 July 2012, but this only licensed Truvada (tenofovir plus emtricitabine) for use in HIV-negative people as a prevention measure; it did not make recommendations as to who should be considered for PrEP. 

The CDC issued previous guidelines in July 2011, well before the FDA approval, and only approximately 750 prescriptions for PrEP were made before FDA approval. Uptake has slowly increased since then but is still surisingly low amongst gay men, with only 9% of physicians ever having prescribed it. The New York Times in an article today comments that the CDC's recommendations "could transform AIDS prevention in the United States" and that, if followed strictly, they would result in a 50-fold increase in Truvada prescriptions a year.    

"HIV infection is preventable, yet every year we see some 50,000 new HIV infections in the United States,” said CDC Director Tom Frieden. “PrEP, used along with other prevention strategies, has the potential to help at-risk individuals protect themselves and reduce new HIV infections in the United States."

Reference

The 67-page guidelines and 44-page clinical providers’ supplement are published in full here and here.

MarketPlace